{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gord-in-children/prescribing-information/gavisconr-infant/","result":{"pageContext":{"chapter":{"id":"775cc2f7-5cf2-5e72-9ffe-a06fbbe7bc17","slug":"gavisconr-infant","fullItemName":"Gaviscon® Infant","depth":2,"htmlHeader":"<!-- begin field 12caa942-9597-4c2a-882b-ea55344085f5 --><h2>Gaviscon® Infant</h2><!-- end field 12caa942-9597-4c2a-882b-ea55344085f5 -->","summary":"","htmlStringContent":"<!-- begin item 72c97858-faf7-4799-b22d-6314d45113a3 --><!-- end item 72c97858-faf7-4799-b22d-6314d45113a3 -->","topic":{"id":"3450f996-245b-5f1c-9e7b-4ac79aed190b","topicId":"82055e52-e2bf-4f1f-b8dd-b6cfff4b5cba","topicName":"GORD in children","slug":"gord-in-children","lastRevised":"Last revised in September 2020","chapters":[{"id":"6dd62a16-ccde-575f-9138-028d0f7249d5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5c4344fa-cc04-5c8a-8525-0117f05a2a3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95a987c9-7f19-57c2-82eb-6673330f1a33","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5a628000-fddd-591e-aa4a-f3a5d27a3b54","slug":"changes","fullItemName":"Changes"},{"id":"76aa1188-2e33-55c6-ba4c-d13b6c09db53","slug":"update","fullItemName":"Update"}]},{"id":"939fae21-c502-5912-ad61-afb229a9fac5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"23c2943f-6ecf-5571-a559-9818348552ba","slug":"goals","fullItemName":"Goals"},{"id":"caee2b08-a4c2-5fa3-8d43-130a043b68d9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5fb28217-0443-5bfa-a971-4909a5a6c93b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"72771ba0-2707-5c43-b059-6d539cc568df","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"33debdff-0f33-531f-b7c3-a3123aa752ac","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b53e0cd-2b10-5e6f-99ad-e832ae9dde2e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0534b6c6-d8fb-5482-910c-3890eccd28a1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b0622c3b-0b7d-5e06-ac6e-b48f44307885","slug":"definition","fullItemName":"Definition"},{"id":"6dc898dd-dd38-5627-be60-ce0f218fcc6f","slug":"causes","fullItemName":"Causes"},{"id":"71b6272e-eb35-5e68-8449-c464d77d7563","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"844a2a73-bae8-5ae2-a218-4de702392498","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7924f80b-3369-54d7-a800-9a0bb22a0242","slug":"complications","fullItemName":"Complications"},{"id":"6ef64f28-7f65-5aaa-8e40-c5ed7f3ead77","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1bff5828-94a1-5984-8ed1-8cde69104288","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fd58f48a-9a7b-50dd-9c0e-d1c4826f6326","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"4ab712ac-c731-5386-8b93-5afa98f37717","slug":"assessment","fullItemName":"Assessment"},{"id":"5e9aff96-e1cf-58e7-9de4-ffdfa742df08","slug":"differential-diagnosis-red-flag-features","fullItemName":"Differential diagnosis/'red flag' features"}]},{"id":"9ac089f7-44bb-5da5-87a5-a065775dcea0","fullItemName":"Management","slug":"management","subChapters":[{"id":"cfa333ea-866c-555f-8a74-08b659ba92cb","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"3c2116b9-ca53-5715-b7ed-02d6e146d463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"775cc2f7-5cf2-5e72-9ffe-a06fbbe7bc17","slug":"gavisconr-infant","fullItemName":"Gaviscon® Infant"},{"id":"0f6b46fc-04ae-528e-8a4f-182488436dd7","slug":"ranitidine","fullItemName":"Ranitidine"},{"id":"81949c9c-d9f4-5246-ba10-93e03d3d5c2b","slug":"omeprazole","fullItemName":"Omeprazole"}]},{"id":"033a9c06-1742-5548-9885-53d54c7cc3b0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"558cd112-f11b-5b2e-a9a9-80f699b1dee5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9f5b615b-0570-5ba7-8d7a-d4cc5a4dd033","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"30b65237-637c-50a8-90fe-3c945c1a3ee1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45d4b60b-a070-544b-9f14-bee3b54e7f3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"58c86f1d-bcc1-59b5-90c0-4a4c75374532","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0691004e-29d1-5b9f-b06e-90eeba4ce3f5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7490205e-5357-534e-bf5f-2f2aad729683","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3c2116b9-ca53-5715-b7ed-02d6e146d463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d2b9a88e-2880-5585-92d3-911458ec4aa5","slug":"dose-administration","fullItemName":"Dose and administration","depth":3,"htmlHeader":"<!-- begin field 27e98062-7e6a-4d85-a4a0-bc22aa58cb47 --><h3>What is the recommended dose and how should it be given? </h3><!-- end field 27e98062-7e6a-4d85-a4a0-bc22aa58cb47 -->","summary":"","htmlStringContent":"<!-- begin item a4db501e-04b3-4240-b44e-e30fbbebb63e --><!-- begin field 27c63c90-a881-4a7a-8d3d-a461f885566a --><p><strong>Gaviscon<sup>® </sup>Infant is supplied as 'dual sachets', and each half of the dual sachet is one 'dose'. </strong><strong>To avoid errors, prescribe with directions in terms of ‘dose’.</strong></p><ul><li><strong>The following doses of Gaviscon<sup>® </sup>Infant are recommended for children aged 1 month to 2 years old</strong><strong>:</strong><ul><li>Body weight up to 4.5 kg — prescribe one 'dose' when required, up to a maximum of 6 times in 24 hours.</li><li>Body weight more than 4.5 kg — prescribe two 'doses' when required, up to a maximum of 6 times in 24 hours.</li></ul></li><li><strong>Advise parents and/or carers on how Gaviscon<sup>® </sup>Infant should be administered.</strong><ul><li>For breastfed infants:<ul><li>Mix the prescribed dose with 5 mL of cooled boiled water to make a smooth paste, then add another 10 mL of cooled boiled water and mix.</li><li>Part way through the feed, use a spoon or feeding bottle to give the dose of Gaviscon<sup>® </sup>Infant.</li></ul></li><li>For formula-fed infants:<ul><li>Mix the prescribed dose into 115 mL of feed in the bottle, shake well, and feed as normal.</li></ul></li><li>Gaviscon<sup>® </sup>Infant can also be given (after mixing with cooled boiled water) at the end of each meal using a spoon or feeding bottle.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">BNF 76, 2018</a>]</p><!-- end field 27c63c90-a881-4a7a-8d3d-a461f885566a --><!-- end item a4db501e-04b3-4240-b44e-e30fbbebb63e -->","subChapters":[]},{"id":"8d38e946-44a9-581f-9c5d-a558382950b7","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ba7fdc51-af54-4205-b5e9-da2404ffe8c1 --><h3>What are the contraindications and cautions?</h3><!-- end field ba7fdc51-af54-4205-b5e9-da2404ffe8c1 -->","summary":"","htmlStringContent":"<!-- begin item 6171ee41-396f-4c6f-a4a5-c1984cf9c2cb --><!-- begin field 621c9499-f58e-466e-b51b-d3ff22ac3f80 --><ul><li><strong>Do not prescribe Gaviscon<sup>® </sup>Infant to children who have:</strong><ul><li>Intestinal obstruction.</li><li>Diarrhoea, or in other situations where excessive water loss is likely, for example, fever, vomiting, or high room temperature.</li><li>Known or suspected renal impairment — Gaviscon<sup>® </sup>Infant has a sodium content of about 21 mg (or 0.92 mmol) per dose and this may increase the risk of hypernatraemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">BNF 76, 2018</a>]</p><!-- end field 621c9499-f58e-466e-b51b-d3ff22ac3f80 --><!-- end item 6171ee41-396f-4c6f-a4a5-c1984cf9c2cb -->","subChapters":[]},{"id":"06c06dbe-891e-5626-bd32-62db2195110a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 155fe184-6346-40fd-91f6-c3aca9247c6c --><h3>What are the posisble adverse effects?</h3><!-- end field 155fe184-6346-40fd-91f6-c3aca9247c6c -->","summary":"","htmlStringContent":"<!-- begin item faecd6d6-0219-421f-881a-12482cd74761 --><!-- begin field 5976fa32-7e8d-4e19-bb16-cf5f054aadde --><ul><li><strong>Possible adverse effects of Gaviscon<sup>® </sup>Infant include:</strong><ul><li>Gastric distension.</li><li>Constipation.</li><li>Diarrhoea.</li><li>Intestinal obstruction.</li><li>Flatulence.</li><li>Bezoar.</li><li>Hypersensitivity.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">ABPI, 2015a</a>] </p><!-- end field 5976fa32-7e8d-4e19-bb16-cf5f054aadde --><!-- end item faecd6d6-0219-421f-881a-12482cd74761 -->","subChapters":[]},{"id":"693d22e4-cff1-5eb6-83ed-dce023671554","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 701e982f-c4cd-4a96-978c-5781ad54580b --><h3>What are the possible drug interactions?</h3><!-- end field 701e982f-c4cd-4a96-978c-5781ad54580b -->","summary":"","htmlStringContent":"<!-- begin item 251247aa-843e-43ae-883a-7c31685ea977 --><!-- begin field 7d8db6a7-48b4-4a3e-9b0b-b54ed9f50861 --><ul><li><strong>Feed thickeners </strong>— do not use Gaviscon<sup>® </sup>Infant with feed thickeners (such as Instant Carobel<sup>®</sup>, Enfamil AR<sup>®</sup>, or SMA Staydown<sup>®</sup>) as this could lead to over-thickening of the stomach contents.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">ABPI, 2015a</a>]</p><!-- end field 7d8db6a7-48b4-4a3e-9b0b-b54ed9f50861 --><!-- end item 251247aa-843e-43ae-883a-7c31685ea977 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}